Navigation Links
Therapeutic potential of embryonic stem cells
Date:6/18/2010

Are stem cells ready for prime time?

The therapeutic potential of embryonic stem cells has been an intense focus of study and discussion in biomedical research and has resulted in technologies to produce human induced pluripotent stem cells (hiPSCs). Derived by epigenetic reprogramming of human fibroblasts, these hiPSCs are thought to be almost identical to human embryonic stem cells (hESCs) and provide great promise for patient-tailored regenerative medicine therapies. However, recent studies have suggested noteworthy differences between these two stem cell types which require additional comparative analyses.

Scientists at Children's Memorial Research Center at Northwestern University Feinberg School of Medicine investigated the expression of key members of the Nodal embryonic signaling pathway, critical to maintaining pluripotency, in hiPSC and hESC cell lines. Nodal is an important morphogen a soluble molecule that can regulate cell fate in embryological systems that requires tight regulatory control of its biological function.

The group's results demonstrated slightly lower levels of Nodal and Cripto-1 (Nodal's co-receptor) and a dramatic decrease in Lefty (Nodal's inhibitory regulator) in hiPSCs compared with hESCs, suggesting less regulatory control of cell fate in reprogrammed stem cells. Based on these findings, additional work addressed the implications associated with the epigenetic reprogramming of hiPSCs and examined a global comparative analysis of 365 microRNAs (miRs) in hiPSC vs. hESC lines.

The data revealed 10 highly expressed miRs in hiPSCs with greater than 10-fold difference, which have been shown to be cancer related. Collectively, these data demonstrate cancer hallmarks expressed by hiPSCs, which will require further elucidation for their impact on clinical applications, especially with respect to the fate of precancerous stem cells.


'/>"/>

Contact: Peggy Jones
pmjones@childrensmemorial.org
773-755-6341
Children's Memorial Hospital
Source:Eurekalert

Page: 1

Related medicine news :

1. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
2. Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
4. Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
5. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
6. Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
7. SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea
8. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
9. The therapeutic benefits of the human-animal bond
10. Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions
11. Echo Therapeutics Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... PRUSSIA, PA and LONDON, UK (PRWEB) , ... May 06, 2016 ... ... earn accolades for his success in changing the way the pharmaceutical industry conducts clinical ... list of the world’s most influential people in pharma, and he was honored as ...
(Date:5/6/2016)... ... May 06, 2016 , ... US Sports Camps has collaborated with State Rugby ... State University this summer. Employing world-class rugby figures, including former Team USA players and ... training on key fundamentals, match play, fitness and more. , “US Sports Camps is ...
(Date:5/6/2016)... ... May 06, 2016 , ... Innovations with Ed ... airing third quarter 2016, via Discovery Channel. Dates and show times TBA. , ... optimized drug discovery through innovative cellular analysis. In this segment, viewers will learn ...
(Date:5/6/2016)... ... ... Online HR/benefits platforms offer a range of benefits functions to employers of all ... “ The Rapid Emergence of Online Benefits Firms: Strategies for Health Plans and Brokers ... an accurate picture of online benefits today, and the possible risks and rewards. Featuring ...
(Date:5/6/2016)... ... ... Mark Black is a speaker, author, and life strategy coach who is spreading the ... help of his publisher Strategic Book Group and its subsidiary Publish on Demand Global ... a miracle: He needed a heart and double-lung transplant. From this came a life-changing transformation ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
Breaking Medicine Technology: